Seven genetic risk factors (DNA sequences) that determine prostate cancer risk have been identified by researchers from the University of Southern California in Los Angeles and Harvard Medical School in Boston.
Seven genetic risk factors (DNA sequences) that determine prostate cancer risk have been identified by researchers from the University of Southern California in Los Angeles and the Harvard Medical School in Boston.
The sequences are grouped in one area of the human genome on chromosome 8 and strongly suggest men’s likelihood of progression to prostate cancer, according to study findings, which were published this week in the online edition of Nature Genetics. The sequences are located outside the coding regions of genes, suggesting novel molecular mechanisms in DNA that may alter risk of disease.
“The study has identified combinations of genetic variants that predict more than a five-fold range of risk for prostate cancer,” said senior author David Reich, DPhil, of Harvard. “Both high- and low-risk combinations of variants are common in human populations.”
Researchers note that understanding these genetic risk factors may help explain the higher risk for prostate cancer among African-Americans, and it may also highlight in general why certain men develop prostate cancer.
Each of the seven genetic variants independently predicts cancer risk, according to the researchers; however, the predictive strength of the cancer varies according to the variant.
“Clinical testing of these genetic variants may help us identify men who should be prioritized for early prostate cancer screening and prevention efforts,” Dr. Reich said.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.